Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.